GLPwatch
Papers (9189)
Page 99 of 154, ranked by citation count.
- Effects of the GLP-1 Receptor Agonist Dulaglutide on the Structure of the Exocrine Pancreas of Cynomolgus Monkeys.
- Comparison of the Effects of Liraglutide on Islet Graft Survival Between Local and Systemic Delivery.
- Glucagon and exenatide improve contractile recovery following ischaemia/reperfusion in the isolated perfused rat heart.
- The efficacy and safety of glucagon-like peptide-1 receptor agonists in non-diabetic adults with overweight/obesity: An umbrella review of systematic reviews and meta-analyses.
- Discontinuing semaglutide after weight loss: strategy for weight maintenance and a possible new side effect.
- Effectiveness and cost-effectiveness of six GLP-1RAs for treatment of Chinese type 2 diabetes mellitus patients that inadequately controlled on metformin: a micro-simulation model.
- Effects of exenatide and liraglutide on 24-hour glucose fluctuations in type 2 diabetes.
- All-cause and diabetes-related healthcare costs among US adults with type 2 diabetes initiating exenatide once weekly or insulin glargine.
- Tirzepatide and health-related quality of life in adults with obesity or overweight: Results from the SURMOUNT-3 phase 3 randomized trial.
- Systemic and gut microbiome changes with metformin and liraglutide in youth-onset type 2 diabetes: the MIGHTY study.
- Within-Trial Evaluation of Medical Resources, Costs, and Quality of Life Among Patients With Type 2 Diabetes Participating in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL).
- Semaglutide (Wegovy) for the Treatment of Obesity.
- Preliminary observations on the administration of a glucagon-like peptide-1 receptor agonist on body weight and select carbohydrate endpoints in persons with spinal cord injury: A controlled case series.
- Exendin-4 inhibits endothelial protein C receptor shedding in vitro and in vivo.
- Oral Semaglutide in an East Asian Population With Overweight or Obesity, With or Without Type 2 Diabetes: The OASIS 2 Randomized Clinical Trial.
- A narrative review of new treatment options for chronic kidney disease in type 2 diabetes.
- Exendin-4-based imaging in endogenous hyperinsulinemic hypoglycaemia cohort: A tertiary Endocrine centre experience.
- Clinical effects of liraglutide are possibly influenced by hypertriglyceridemia and remaining pancreatic β-cell function in subjects with type 2 diabetes mellitus.
- A multiplicity of targets: evaluating composite endpoint studies of the GLP-1 receptor agonists in type 2 diabetes.
- Once-Weekly Dulaglutide for Treatment of Youths with Type 2 Diabetes. Reply.
- Optoacoustic Imaging of Glucagon-like Peptide-1 Receptor with a Near-Infrared Exendin-4 Analog.
- Perspectives on weight control in diabetes - Tirzepatide.
- Exenatide once weekly versus daily basal insulin as add-on treatment to metformin with or without a sulfonylurea: a retrospective pooled analysis in patients with poor glycemic control.
- Meta-Analysis Assessing the Cardiovascular Safety of Semaglutide for the Treatment of Overweight or Obesity.
- Non-invasive glucagon-like peptide-1 receptor imaging in pancreas with (18)F-Al labeled Cys(39)-exendin-4.
- New practice in semaglutide on type-2 diabetes and obesity: clinical evidence and expectation.
- Impact of semaglutide on lipid profiles in overweight and obese non-diabetic adults: A systematic review and meta-analysis of randomized controlled trials.
- Comparative Effects of Randomized Second-line Therapy for Type 2 Diabetes on a Composite Outcome Incorporating Glycemic Control, Body Weight, and Hypoglycemia: An Analysis of the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE).
- Effect of GLP-1 receptor agonists on body composition.
- Semaglutide as a potential therapeutic alternative for HNF1B-MODY: a case study.
- Role of incretin-based therapies and sodium-glucose co-transporter-2 inhibitors as adjuncts to insulin therapy in Type 2 diabetes, with special reference to IDegLira.
- Treatment of type 2 diabetes in children: what are the specific considerations?
- Effects of glucagon-like peptide-1 receptor agonists on spermatogenesis-related gene expression in mouse testis and testis-derived cell lines.
- Semaglutide for weight loss.
- Evaluation of gastric content in fasting patient during semaglutide use: an observational study.
- Glucagon-like Peptide-1 Receptor Analogues for the Treatment of Obesity.
- Pharmacological interventions for addressing pediatric and adolescent obesity: A systematic review and network meta-analysis.
- The Effectiveness and Value of Oral Semaglutide for Type 2 Diabetes Mellitus.
- Ex vivo lung perfusion with GLP-1R agonist mitigates ischemia/reperfusion injury through pyroptosis modulation in lung transplantation- an experimental study.
- Impact of glucagon-like peptide-1 receptor agonists on axonal function in diabetic peripheral neuropathy.
- iGlarLixi provides a higher derived time-in-range versus insulin glargine 100 U/mL or lixisenatide in Asian Pacific people with type 2 diabetes: A post hoc analysis.
- In overweight or obesity without diabetes, weekly semaglutide vs. daily liraglutide increased weight loss at 68 wk.
- Once-weekly exenatide: an extended-duration glucagon-like peptide agonist for the treatment of type 2 diabetes mellitus.
- Extrapancreatic effects of incretin hormones: evidence for weight-independent changes in morphological aspects and oxidative status in insulin-sensitive organs of the obese nondiabetic Zucker rat (ZFR).
- Interest in Treatment with GLP-1 Receptor Agonists for the Management of Insufficient Weight Loss or Weight Regain After Bariatric Surgery.
- Pancreatic safety of GLP-1-based therapeutic agents: further insights from rodent studies?
- Nonarteritic Anterior Ischemic Optic Neuropathy and Semaglutide: What is This All About?
- Acute Pancreatitis Caused by Tirzepatide.
- Real-world clinical effectiveness of once-weekly semaglutide in patients with type 2 diabetes: a systematic literature review.
- The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Baseline Patient-Reported Outcomes.
- Systematic Design of Trypsin Cleavage Site Mutated Exendin4-Cysteine 1, an Orally Bioavailable Glucagon-Like Peptide-1 Receptor Agonist.
- Safety and Efficacy of Tirzepatide in Solid-Organ Transplant Recipients: Experience of a Quaternary Care Center in the Middle East.
- Managing Diabetes and Preventing Heart Disease: Have We Found a Safe and Effective Agent?
- Influence of chronic kidney disease and its severity on the efficacy of semaglutide in type 2 diabetes patients: a multicenter real-world study.
- Rationale for treatment options for mealtime glucose control in patients with type 2 diabetes.
- Liraglutide in heart failure: caution is needed.
- A genetic screen identifies Crat as a regulator of pancreatic beta-cell insulin secretion.
- Effect of liraglutide on neural and peripheral markers of metabolic function during antipsychotic treatment in rats.
- Liraglutide promotes UCP1 expression and lipolysis of adipocytes by promoting the secretion of irisin from skeletal muscle cells.
- The cost-effectiveness of semaglutide in reducing cardiovascular risk among people with overweight and obesity and existing cardiovascular disease, but without diabetes.